Granules India: Latest Updates

Financial Results (Q4 & FY26) Strong Q4 Growth: On April 29, 2026, Granules India reported a 32.5% increase in net profit for the fourth quarter, reaching ₹201.56 crore. Revenue for the quarter rose 23% year-on-year to ₹1,470.6 crore, driven by robust demand in the US generics market. Profitability Boost: Gross margins improved to 65%, largely due to a strategic shift from high-volume products toward higher-margin Complex Generics, which now account for 43% of the finished dosage portfolio. Dividends and Corporate Actions Final Dividend: The Board has recommended a final dividend of ₹1.75 per equity share (175% of face value) for FY26. Record Date: The company has fixed July 30, 2026, as the record date for determining shareholder eligibility for this dividend payment. Debt Reduction: The company significantly strengthened its balance sheet, reducing its net debt-to-EBITDA ratio to 0.34x, down from 0.75x in the previous year. Regulatory and USFDA Updates Chantilly Facility Audit: In early April 2026, the US FDA completed a routine inspection of the company’s Chantilly (Virginia) facility. The audit concluded with four procedural observations (Form 483), but notably, no data integrity issues were found. Compliance Momentum: The company’s subsidiary, Granules Life Sciences, recently received a Voluntary Action Indicated (VAI) classification for its Shamirpet facility, while the US unit (GPI) achieved a targeted operating potential, ranking 27th among US generic companies by sales value. Expansion and New Verticals Peptide CDMO Success: The newly established Peptide CDMO (Contract Development and Manufacturing) vertical, launched after the acquisition of Senn Chemicals, turned EBITDA positive in Q4 FY26, contributing ₹159 crore to annual revenue. Pipeline: The company is currently awaiting clearance for 9 product applications from its Gagillapur site, focusing on controlled substances and oncology products.